ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT 2024
Zinzino group revenue increased 34% in Q4 and total revenue for the full year 2024 increased 25%, compared with the previous year.
The revenue in December for Zinzino's sales markets increased by 59 % and amounted to SEK 239.6 (150.3) million. Faun Pharma's external sales increased and amounted to SEK 5.6 (5.1) million. Overall, the Group increased revenues by 58% to SEK 245.2 (155.4) million compared with the previous year.
Sales in Zinzino's sales markets increased by 34% in the fourth quarter of 2024 compared with the same period last year and amounted to SEK 683.0 (509.1) million. Total revenue in the Group increased by 34 % in the fourth quarter and amounted to SEK 706.1 (527.9) million.
Accumulated revenue for January – December 2024 increased by 25% to SEK 2200.4 (1766.4) million.
Revenues were distributed as follows:
| Regions, mSEK | 24-Dec | 23-Dec | Change | Q4 2024 | Q4 2023 | Change | YTD 2024 | YTD 2023 | Change | |
| The Nordics | 29,1 | 26,3 | 11% | 87,5 | 82,8 | 6% | 301,5 | 299,9 | 1% | |
| Central Europe | 73,2 | 43,7 | 68% | 197,5 | 135,2 | 46% | 591,9 | 438,3 | 35% | |
| East Europe | 34,8 | 32,1 | 8% | 120,8 | 113,1 | 7% | 400,7 | 394,3 | 2% | |
| South & West Europe | 50,5 | 23,7 | 113% | 132,8 | 85,5 | 55% | 397,3 | 265,7 | 50% | |
| The Baltics | 12,0 | 8,2 | 46% | 38,3 | 31,2 | 23% | 107,7 | 98,0 | 10% | |
| North America | 21,5 | 10,3 | 109% | 66,6 | 42,7 | 56% | 200,6 | 110,5 | 82% | |
| Asia-Pacific | 16,8 | 5,1 | 229% | 33,7 | 15,4 | 119% | 81,2 | 56,4 | 44% | |
| Africa | 1,7 | 0,9 | 89% | 5,9 | 3,2 | 83% | 16,8 | 13,2 | 27% | |
| Zinzino | 239,6 | 150,3 | 59% | 683,0 | 509,1 | 34% | 2 097,7 | 1 676,3 | 25% | |
| Faun Pharma | 5,6 | 5,1 | 10% | 23,0 | 18,8 | 22% | 102,7 | 90,1 | 14% | |
| Zinzino Group | 245,2 | 155,4 | 58% | 706,1 | 527,9 | 34% | 2 200,4 | 1 766,4 | 25% | |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, www.zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: Carnegie Investment Bank AB (publ.)
Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Swiss, biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia and Australia.